Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
What Is Symblepharon? | OBN
What Is Symblepharon? Symblepharon is a medical condition characterized by the adhesion of the conjunctiva, the clear membrane that covers the white part of the eye and the inside of the eyelids, to the cornea, the clear front part of…
Top 10 Ophthalmologists Who Changed the Field
Ophthalmology, the branch of medicine that deals with the diagnosis and treatment of eye-related diseases and disorders, has made great strides in the past century. The following ten individuals are among the most influential and accomplished ophthalmologists in history, each…
CHMP Issues Negative Opinion on Syfovre for Geographic Atrophy
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) delivered a negative opinion on the marketing authorization application (MAA) for Apellis Pharmaceuticals’ Syfovre (pegcetacoplan), intended for the treatment of geographic atrophy (GA). CHMP’s Assessment…
Antibiotics Help Prevent Infections in Cataract Patients
A recent study published in JAMA Ophthalmology has highlighted the effectiveness of selective intracameral antibiotics combined with 1% povidone iodine in reducing the incidence of postoperative endophthalmitis after cataract surgery. Led by Jeroen van Rooij, MD, from Rotterdam Eye Hospital,…
Novel AI Boosts Geographic Atrophy Clinical Trial Efficiency
A new artificial intelligence (AI) system developed by researchers from UCL and Moorfields Eye Hospital could potentially revolutionize the recruitment process for clinical trials aimed at treating Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that…
VSY Biotechnology: Who Will Shine at the OSA 2024?
VSY Biotechnology GmbH, a leading company with innovative ophthalmic solutions, is now accepting submissions for Ophthalmology Star Awards (OSA) 2024 from eye care professionals worldwide. The awards aim to celebrate and promote novel research and advancements in ophthalmology, with winners…
NVISION Eye Centers Partners with Parkhurst NuVision
NVISION Eye Centers, a prominent provider of eye care services nationwide, announced a strategic collaboration with Parkhurst NuVision of San Antonio, Texas, through its subsidiary NVision Clinical Research, LLC. This partnership aims to advance clinical trials in ophthalmology drug development,…
Notal Vision’s OCT Promises Advances in Wet AMD Management
Notal Vision announced findings from a pioneering clinical trial using home-based optical coherence tomography (OCT) to oversee patients with wet age-related macular degeneration (AMD). Published in Retina, the results highlighted a notable reduction in office visits and treatment frequency, while…
ANI Pharmaceuticals to Acquire Alimera Sciences in $381M Deal
ANI Pharmaceutical has signed a definitive agreement to acquire Alimera at approximately $381 million. The agreement has been approved by both companies’ Boards of Directors and is anticipated to close in the late third quarter of 2024. Alimera Sciences, a…
4DMT Receives FDA Clearance of IND for GA Treatment
4D Molecular Therapeutics (4DMT) announced the FDA clearance of its investigational new drug application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine intended for treating geographic atrophy (GA) in patients. Phase 1 GAZE Clinical Trial Details The phase 1…